Wednesday, October 24, 2012 11:12:32 AM
I have to disagree with you on those points. I do believe BPs will not ignore the data for these other trials and will prompt them to continue the deal making process.
BPs are not the ignorant investment community at large. If the screw up was indeed due to a 3rd party screw up and we do actually have a significant number of long term survivals occurring (still find that fact very hard to fake) then I cannot see how a knowledgeable BP would ignore the information from other uncontaminated trials. Doesn't make sense to me that they would ignore positive randomized trial data.
The vast majority of Phase 2 trials are of the type we are using for front line NSCLC and for the pancreatic cancer trial (not to mention all the other IST data just waiting to provide a surprise). Also, IMO, these trials carry much less risk of hidden gotchas like the double blind trials have because a company is not at the mercy of other companies' performance. I guess this also means I don't agree with your statement:
IMO, there are significantly more process type traps imbedded in the double blind process that makes it much easier to screw up the performance/application of the double blinded trial than a plain randomized trial, especially from the point of view of the company paying for the trial. The company paying for the trial is the most motivated to see it done properly and, here in the double blind process they have to pass off these duties to 3rd party vendors who IMO aren't anywhere near as motivated in attention to detail.
These randomized trials may not create the level of belief in the efficacy that the double blind trial does but again its rare to use a double blind format at this stage of the game anyway. Lots of companies get great boosts from trial results from these types of randomized trials.
The ATM cannot be turned off until they get another source of funds and if these other trials provide valid data then I see no reason why they won't be granted access to funding.
Nothing yet has come close to proving that the management team was deliberately withholding bad information for an inappropriate amount of time or purposely misleading investors. Don't get me wrong on this subject. I have my doubts on their ability to manage trial processes but I prefer not to go there anymore. The ASM is over and there is no benefit for me to discuss this subject further.
The funding institutions will make their determinations on this subject when the time comes for PPHM to approach them for more funding. If they get another good substantial loan based on trial data then the ATM should again be put on hold and the stock price should benefit positively from this.
Bottom line here is that we are just going to have to disagree on the catalyst potential for the randomized front line and pancreatic trials and what BPs and lending institutions think about Peregrine management's trustworthiness. I believe we only have 2 - 4 months at the most to find out.
Take it easy Eyebuy.
Recent CDMO News
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM